Q2 2026 Organic Revenue Slightly Declines Despite 30% Total Revenue Surge

What happened

Brown & Brown reported Q2 2026 total revenues of $1.7B, up 30.4% year-over-year, driven by the transformative Accession acquisition, but organic revenue dipped 0.7% (or +0.7% including contingents), missing the mid-single-digit growth embedded in our BUY thesis. Diluted adjusted EPS of $1.07 reflects the earnings power of the enlarged platform, though the quarterly organic contraction raises questions about underlying demand and retention. The earlier DeepValue report highlighted integration KPIs and organic growth as key watch items; this print triggers the low-growth caution flag, shifting the near-term risk/reward. While the total revenue expansion demonstrates the scale benefits of the Accession deal, the negative organic growth suggests either pricing headwinds or integration disruption that we previously flagged as a risk. Management’s ability to reverse this organic trend through cross-sell and specialty strength will be critical to restoring confidence in the compounding story.

Implication

Long-term thesis hinges on whether the Accession integration can deliver sustained organic growth; failure risks a de-rating to lower-growth broker multiples.

Thesis delta

The Q2 2026 organic revenue decline directly challenges the core assumption of mid-single-digit organic growth underpinning our BUY stance. This print moves the thesis closer to a HOLD given the elevated uncertainty around integration and market conditions. We will monitor subsequent quarters for stabilization; if organic growth remains negative or flattish, a downgrade to HOLD/REDUCE is warranted.